Character Biosciences

Character Biosciences is a precision medicine platform with the slogan "A patient-driven drug discovery platform for diseases of aging." The company, formerly known as Clover Therapeutics, is focused on unlocking the patterns of age-related diseases in diverse populations. Founded in 2018, their mission is to use human genetics to understand the underlying causes of diseases with the aim of discovering targeted therapies for more effective treatments, particularly for patients lacking treatment options. Character Biosciences partners with patients, providers, payers, and scientists to create deeply-phenotyped patient cohorts and to enable clinical genomic research. Their approach integrates genomics, longitudinal clinical and imaging data, machine learning, and novel experimental approaches to identify molecular drivers of disease progression and develop innovative targeted medicines. The company operates within the Biotechnology, Health Care, and Pharmaceutical industries and is based in the United States. Their most recent investment was a Series A investment on 2nd September 2022, with Shane Neman being the investor. Overall, Character Biosciences' focus on precision medicine, patient-centric approach, and innovative methodologies for drug discovery position them as a promising player in addressing diseases of aging through targeted therapies.